Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must have endoscopically confirmed erosive esophagitis as defined by the Los Angeles (LA) Classification Grading System (A-D)~Exclusion Criteria:~* Subject has a positive Campylobacter-like organisms (CLO) test for Helicobacter (H.) pylori.~* Use of prescription or non-prescription proton pump inhibitors (PPIs), histamine (H2) receptor antagonists or sucralfate, drugs with significant anticholinergic effects, misoprostol or prokinetics~* Use of antacids \[except for study supplied Gelusil®\]~* Need for continuous anticoagulant therapy (blood thinners)~* Endoscopic Barrett's esophagus and/or definite dysplastic changes in the esophagus~* History of dilatation of esophageal strictures, other than Schatzki's ring (a ring of mucosal tissue near the lower esophageal sphincter)~* Current or historical evidence of Zollinger-Ellison syndrome or other hypersecretory condition.~* History of gastric, duodenal or esophageal surgery except simple oversew of an ulcer.~* Acute upper gastrointestinal hemorrhage within 4 weeks of the screening endoscopy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexlansoprazole MR 60 mg QD (Type: EXPERIMENTAL): None
- Dexlansoprazole MR 90 mg QD (Type: EXPERIMENTAL): None
- Lansoprazole 30 mg QD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).